SE0103509D0 - Rosuvastatin in pre demented states - Google Patents
Rosuvastatin in pre demented statesInfo
- Publication number
- SE0103509D0 SE0103509D0 SE0103509A SE0103509A SE0103509D0 SE 0103509 D0 SE0103509 D0 SE 0103509D0 SE 0103509 A SE0103509 A SE 0103509A SE 0103509 A SE0103509 A SE 0103509A SE 0103509 D0 SE0103509 D0 SE 0103509D0
- Authority
- SE
- Sweden
- Prior art keywords
- demented
- rosuvastatin
- states
- dementia
- rosuvastiatin
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title 1
- 229960000672 rosuvastatin Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
| ARP020103895A AR036891A1 (es) | 2001-10-19 | 2002-10-17 | Rosuvastatina en estados predemenciales |
| RU2004112422/14A RU2004112422A (ru) | 2001-10-19 | 2002-10-18 | Роувастатин в преддеменционных состояниях |
| BR0213434-9A BR0213434A (pt) | 2001-10-19 | 2002-10-18 | Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável |
| MXPA04003631A MXPA04003631A (es) | 2001-10-19 | 2002-10-18 | Rosuvastatina en estados de pre-demencia. |
| KR10-2004-7005585A KR20040058201A (ko) | 2001-10-19 | 2002-10-18 | 치매전 상태에 사용되는 로수바스타틴 |
| US10/492,971 US20060229321A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
| JP2003535798A JP2005505605A (ja) | 2001-10-19 | 2002-10-18 | 前痴呆状態におけるロスバスタチン |
| PL02369573A PL369573A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
| EP02783893A EP1446123A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
| IL16138002A IL161380A0 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
| CNA028253477A CN1604780A (zh) | 2001-10-19 | 2002-10-18 | 在前痴呆状态中使用罗苏伐他汀 |
| CA002463597A CA2463597A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
| HU0401798A HUP0401798A3 (en) | 2001-10-19 | 2002-10-18 | Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states |
| PCT/SE2002/001911 WO2003032995A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
| IS7218A IS7218A (is) | 2001-10-19 | 2004-04-13 | Notkun rósúvastatíns á forstigi vitglapa |
| ZA200402844A ZA200402844B (en) | 2001-10-19 | 2004-04-15 | Rosuvastatin in pre demented states. |
| CO04035705A CO5580773A2 (es) | 2001-10-19 | 2004-04-19 | Rosuvastatina en estados pre dementes |
| NO20041840A NO20041840L (no) | 2001-10-19 | 2004-05-05 | Rosuvastatin ved predemente tilstander |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0103509D0 true SE0103509D0 (sv) | 2001-10-19 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (enExample) |
| EP (1) | EP1446123A1 (enExample) |
| JP (1) | JP2005505605A (enExample) |
| KR (1) | KR20040058201A (enExample) |
| CN (1) | CN1604780A (enExample) |
| AR (1) | AR036891A1 (enExample) |
| BR (1) | BR0213434A (enExample) |
| CA (1) | CA2463597A1 (enExample) |
| CO (1) | CO5580773A2 (enExample) |
| HU (1) | HUP0401798A3 (enExample) |
| IL (1) | IL161380A0 (enExample) |
| IS (1) | IS7218A (enExample) |
| MX (1) | MXPA04003631A (enExample) |
| NO (1) | NO20041840L (enExample) |
| PL (1) | PL369573A1 (enExample) |
| RU (1) | RU2004112422A (enExample) |
| SE (1) | SE0103509D0 (enExample) |
| WO (1) | WO2003032995A1 (enExample) |
| ZA (1) | ZA200402844B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| US7244844B2 (en) | 2003-12-02 | 2007-07-17 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| JP2007508379A (ja) | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法 |
| CA2680693A1 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
| MX2007004427A (es) | 2005-08-16 | 2007-06-14 | Teva Pharma | Intermedio de rosuvastatina cristalina. |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003032995A8 (en) | 2004-06-03 |
| JP2005505605A (ja) | 2005-02-24 |
| ZA200402844B (en) | 2005-01-24 |
| EP1446123A1 (en) | 2004-08-18 |
| NO20041840L (no) | 2004-05-05 |
| PL369573A1 (en) | 2005-05-02 |
| CN1604780A (zh) | 2005-04-06 |
| BR0213434A (pt) | 2004-11-09 |
| MXPA04003631A (es) | 2004-07-30 |
| CO5580773A2 (es) | 2005-11-30 |
| RU2004112422A (ru) | 2005-04-10 |
| AR036891A1 (es) | 2004-10-13 |
| HUP0401798A3 (en) | 2005-06-28 |
| IS7218A (is) | 2004-04-13 |
| WO2003032995A1 (en) | 2003-04-24 |
| HUP0401798A2 (hu) | 2005-01-28 |
| IL161380A0 (en) | 2004-09-27 |
| KR20040058201A (ko) | 2004-07-03 |
| CA2463597A1 (en) | 2003-04-24 |
| US20060229321A1 (en) | 2006-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| ATE240744T1 (de) | Verwendung von csf-1-inhibitoren | |
| ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
| DE60124684D1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
| EP1622633A4 (en) | Treatment of t-cell mediated diseases | |
| DK1296671T3 (da) | Gabapentinanaloger til sövnforstyrrelser | |
| DE60331187D1 (de) | Kinaseinhibitoren | |
| RU2005108133A (ru) | Дипептиднитрильные ингибиторы катепсина к | |
| DE60127537D1 (de) | VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE | |
| DE60139466D1 (de) | Behandlung von diabetes | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| NO20051892L (no) | Ny forbindelse | |
| SE0103509D0 (sv) | Rosuvastatin in pre demented states | |
| NO20051893L (no) | Ny forbindelse | |
| TNSN06138A1 (fr) | Inhibitors of the mutant form of kit | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
| ATE357912T1 (de) | Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten | |
| ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
| DK0583271T3 (da) | Arylmorpholin, fremstilling og anvendelse | |
| DE50010234D1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
| DE60200160D1 (de) | Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen | |
| JP2005505605A5 (enExample) | ||
| SE0004827D0 (sv) | Therapeutic compounds | |
| DE60315666D1 (de) | Furopyridin- und furopyrimidinderivate zur behandlung von hyperproliferativen erkrankungen |